Physician profile
Lydia Robert
NPI 1922865336
$1,367.99
in general payments reported to CMS, 2019-2025
15 companies · $777 in 2025
The $777 reported for 2025 was more than what 84% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $591 · 2025: $777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,293 · Education: $74.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,293.37 |
| Education | $74.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $275.88 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $174.83 | 2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $170.32 | 2024-2025 | Jynarque, Voyxact |
| Veloxis Pharmaceuticals, INC. | $113.96 | 2024 | Envarsus |
| Astrazeneca Pharmaceuticals Lp | $101.25 | 2024-2025 | Farxiga |
| Novo Nordisk INC | $87.04 | 2025 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $71.07 | 2024-2025 | Livtencity |
| Merck Sharp & Dohme LLC | $65.37 | 2025 | Prevymis |
| Amgen INC. | $63.59 | 2025 | Krystexxa |
| Lilly USA, LLC | $62.14 | 2024 | Jardiance |
| Mallinckrodt Hospital Products INC. | $59.72 | 2024-2025 | Terlivaz |
| Akebia Therapeutics INC | $44.55 | 2025 | Vafseo, Auryxia |
| Novartis Pharmaceuticals Corporation | $38.40 | 2024 | |
| Ani Pharmaceuticals, INC. | $25.17 | 2025 | Purified Cortrophin Gel |
| Scpharmaceuticals INC. | $14.70 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lydia Robert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.